Advertisement
Research Article

Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort

  • Jane E. Salmon mail,

    salmonj@hss.edu

    Affiliation: Autoimmunity and Inflammation Program, Hospital for Special Surgery, Cornell Weill Medical College, New York, New York, United States of America

    X
  • Cara Heuser,

    Affiliation: Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Michael Triebwasser,

    Affiliation: Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • M. Kathryn Liszewski,

    Affiliation: Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • David Kavanagh,

    Affiliation: Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom

    X
  • Lubka Roumenina,

    Affiliation: Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Immunologie Biologique, Paris, France

    X
  • D. Ware Branch,

    Affiliation: Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Tim Goodship,

    Affiliation: Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom

    X
  • Veronique Fremeaux-Bacchi,

    Affiliation: Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Immunologie Biologique, Paris, France

    X
  • John P. Atkinson

    Affiliation: Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Published: March 22, 2011
  • DOI: 10.1371/journal.pmed.1001013

About the Authors

Jane E. Salmon
Autoimmunity and Inflammation Program, Hospital for Special Surgery, Cornell Weill Medical College, New York, New York, United States of America
Cara Heuser, D. Ware Branch
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, United States of America
Michael Triebwasser, M. Kathryn Liszewski, John P. Atkinson
Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America
David Kavanagh, Tim Goodship
Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom
Lubka Roumenina, Veronique Fremeaux-Bacchi
Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Immunologie Biologique, Paris, France

Corresponding Author

Email: salmonj@hss.edu

Competing Interests

JES holds stock in Taligen Therapeutics. JPA is on the Scientific Advisory Board and holds stock in Taligen Therapeutics. TG has acted as a Scientific Advisor for Taligen Therapeutics. All other authors have no conflict of interest.

Author Contributions

Conceived and designed the experiments: JES JAP MT VFB TG. Performed the experiments: VFB LR DK MKL TG. Analyzed the data: JES JAP TG MT VFB. Contributed reagents/materials/analysis tools: CH DWB DK MT MKL VBF TG JAP JES. Wrote the paper: JES MT MKL DK VFB JPA. ICMJE criteria for authorship: JES CH MT MKL DK LR DWB TG VFB JPA. Agree with result and conclusions: JES CH MT MKL DK LR DWB VFB TG JPA. Enrolled patients: CH JES DWB TG VFB. Wrote the first draft: JES CH MT MKL DK VFB JPA.